BostonGene Corporation announced that three abstracts were selected for presentation at the United States and Canadian Academy of Pathology (USCAP) 112th Annual Meeting.
WALTHAM, Mass.--(BUSINESS WIRE)-- BostonGene Corporation announced that three abstracts were selected for presentation at the United States and Canadian Academy of Pathology (USCAP) 112th Annual Meeting. The event will be held from March 11 - 16, 2023, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. BostonGene will exhibit in booth #457.
“We are pleased to present BostonGene-supported research at the USCAP Annual Meeting, demonstrating the power of next-generation multi-platform AI-driven analytics. The findings show specific tumor microenvironment subtypes that can provide new avenues for cancer therapeutics and the ability of RNA sequencing to validate pathological assessment of cancer-relevant biomarkers,” said Nathan Fowler, MD, Chief Medical Officer at BostonGene.
Details of the presentations are below:
Title: Immunohistochemistry Predictive Biomarkers Correlate with RNA-Seq Expression Values in Solid Carcinomas
Abstract: 895
Time and Location: Tuesday, March 14, 2023 | 1:00 PM - 4:30 PM, Exhibit Hall B
Presenter: Ekaterina Postovalova, PhD, BostonGene
Emerging as an important precision oncology tool for gene expression analysis, RNA sequencing (RNA-seq) offers valuable information that can validate immunohistochemistry (IHC) assay results while maximizing clinical findings. This presentation demonstrates the correlation of select cancer-relevant gene expression values from RNA-seq with IHC expression in solid carcinomas, highlighting the clinical utility of RNA-seq and the importance of transcriptomic profiling for the assessment of cancer biomarkers for clinical decision making.
Title: Reconstruction of the Metastatic Castration-Resistant Prostate Tumor Microenvironment with Comprehensive Profiling Reveals Unique Subtypes
Abstract: 1250
Time and Location: Tuesday, March 14, 2023 | 9:30 AM - 12:00 PM, Exhibit Hall B
Presenter: Ahmed Elsaeed, MD, Weill Cornell Medicine
Androgen receptor-independent metastatic castration-resistant prostate cancer (mCRPC) represents up to 25-30% of lethal prostate cancer. This study successfully identified five novel tumor microenvironment (TME) subtypes by performing unsupervised clustering on a meta-cohort and an independent cohort. These subtypes with molecular characteristics are associated with histology, sample site, and clinical annotations, which can help further molecular stratification with potential clinical-pathologic significance.
Research conducted with Weill Cornell Medicine
Title: Reconstruction of the Glioblastoma (GBM) Tumor Microenvironment (TME) with Comprehensive Profiling Reveals Unique Subtypes
Abstract: 1122
Time and Location: Tuesday, March 14, 2023 | 9:30 AM - 12:00 PM, Exhibit Hall B
Presenter: Majd Al Assaad, MD, Weill Cornell Medicine
Tumor heterogeneity presents a significant challenge for effective cancer therapies in glioblastoma (GBM), which is the most prevalent primary brain cancer of adults. To understand this heterogeneity, transcriptomic profiling was used on a meta-cohort and an independent cohort, identifying five novel tumor microenvironment (TME) subtypes that are distinguished by differences in gene expression and cellular composition that are associated with histology, sample site, and clinical outcomes.
Research conducted with Weill Cornell Medicine
In addition to the poster presentations, all abstracts accepted for presentation are published in an online-only supplement of either Modern Pathology or Laboratory Investigation. The supplement will be released on Monday, March 13, 2023.
For more information, please visit the USCAP Annual Meeting website.
About BostonGene Corporation
BostonGene’s mission is to power healthcare’s transition to personalized medicine using AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics. BostonGene Tumor PortraitTM Tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene Tumor PortraitTM Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at http://www.BostonGene.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230307005235/en/
Source: BostonGene Corporation
View this news release online at:
http://www.businesswire.com/news/home/20230307005235/en
